Sequel, a new tampon design, which has recently been cleared by the Food and Drug Adminstration to be marketed in the U.S., will be present at Hygienix. The tampon, which offers a patented leak-proof design, took four years for co-founders Amanda Calabrese and Greta Meyer to design. Approval from the FDA marks a critical step in enabling Sequel to bring its tampon–which is designed to be more comfortable and less prone to leakage–to market and reinvigorate a space that has been flooded with private label newcomers, but little product differentiation.

As a part of the FDA clearance process, Sequel performed extensive testing and documentation of the safety and efficacy of the product, which validates the company’s confidence in the design of the Sequel Spiral Tampon.

“FDA clearance has been a long process for us, and we know that this is one of the largest barriers to entry for new products in this category,” says Greta Meyer, co-founder and CEO of Sequel. “However, we understand the importance of these devices being held to the highest standards of safety and quality. We are proud of the work our team has done to reach this milestone for Sequel.”

Meyer, together with Shlomo Helvits, technical manager of Albaad, Sequel's manufacturing partner, will together present at Hygienix on the company's journey to bring an innovative tampon design to market.

Additionally, Sequel is one of three finalists for the Hygienix 2023 Innovation Award.